Patents Assigned to Kadmon Corporation, LLC
  • Method of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease
    Publication number: 20240408095
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with cGVHD.
    Type: Application
    Filed: August 21, 2024
    Publication date: December 12, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: David Eiznhamer, Heidi Krenz
  • Glucose Uptake Inhibitors
    Publication number: 20240360085
    Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUT3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
    Type: Application
    Filed: May 23, 2024
    Publication date: October 31, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Kevin G. Liu, Kellen Olszewski, Ji-In Kim, Masha V. Poyurovsky, Koi Morris, Xuemei Yu, Christophe Lamarque
  • Methods of Administering Belumosudil in Combination with CYP3A Inducers and/or Proton Pump Inhibitors
    Publication number: 20240350493
    Abstract: The present disclosure relates to the co-administration of Belumosudil with CYP3A Inducers and/or Proton Pump Inhibitors for use in the treatment of subjects with chronic graft-versus-host disease (cGVHD).
    Type: Application
    Filed: April 24, 2024
    Publication date: October 24, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Methods of administering Belumosudil for treatment of chronic graft versus host disease
    Patent number: 12097202
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: September 24, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: David Eiznhamer, Heidi Krenz
  • Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations
    Publication number: 20240277713
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to certain subpopulations of patients with cGVHD.
    Type: Application
    Filed: March 27, 2024
    Publication date: August 22, 2024
    Applicant: Kadmon Corporation, LLC
    Inventor: Jeegar P. Patel
  • Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
    Publication number: 20240262810
    Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
    Type: Application
    Filed: March 5, 2024
    Publication date: August 8, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Glucose uptake inhibitors
    Patent number: 12030857
    Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 9, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: Kevin G. Liu, Kellen L. Olszewski, Ji-In Kim, Masha V. Poyurovsky, Koi Morris, Xuemei Yu, Christophe Lamarque
  • Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase
    Publication number: 20240190827
    Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: February 7, 2024
    Publication date: June 13, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
  • Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
    Patent number: 11952369
    Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: April 9, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Inhibitors of Rho associated coiled-coil containing protein kinase
    Patent number: 11926596
    Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2 having the formula I: Also provided are methods of inhibiting ROCK1 and/or ROCK2 useful for the treatment of disease.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: March 12, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
  • Methods of Administering Belumosudil in Combination with CYP3A Inducers and/or Proton Pump Inhibitors
    Publication number: 20240024322
    Abstract: The present disclosure relates to the co-administration of Belumosudil with CYP3A Inducers and/or Proton Pump Inhibitors for use in the treatment of subjects with chronic graft-versus-host disease (cGVHD).
    Type: Application
    Filed: February 3, 2023
    Publication date: January 25, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations
    Publication number: 20240024323
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to certain subpopulations of patients with cGVHD.
    Type: Application
    Filed: February 3, 2023
    Publication date: January 25, 2024
    Applicant: Kadmon Corporation, LLC
    Inventor: Jeegar P. Patel
  • Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
    Publication number: 20240025881
    Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
    Type: Application
    Filed: February 3, 2023
    Publication date: January 25, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease
    Publication number: 20240024321
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients and modifying the administration based on the results of such identification.
    Type: Application
    Filed: February 3, 2023
    Publication date: January 25, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: David Eiznhamer, Heidi Krenz
  • Anti-PD-1 Antibodies and Fusion Proteins
    Publication number: 20230416363
    Abstract: Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.
    Type: Application
    Filed: June 23, 2021
    Publication date: December 28, 2023
    Applicant: Kadmon Corporation, LLC
    Inventors: Dan Lu, Zhanna Polonskaya, Tzu-Pei Chang, Stella Aviaty Martomo, Jeegar P. Patel, Faical Miyara
  • Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
    Publication number: 20230381179
    Abstract: The present disclosure relates generally to the treatment of patients with chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation by administering belumosudil at certain dosages.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 30, 2023
    Applicant: Kadmon Corporation, LLC
    Inventors: Sanjay Aggarwal, Mark Berger, David Eiznhamer, Jeegar P. Patel, Olivier Schueller
  • Human Anti-VEGFR-2/KDR Antibodies
    Publication number: 20230338524
    Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 26, 2023
    Applicant: Kadmon Corporation, LLC
    Inventors: Dan Lu, Zhenping Zhu
  • B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins
    Publication number: 20230312724
    Abstract: Provided herein are recombinant antibodies, antigen-binding fragments thereof, and fusion proteins thereof useful for binding to and inhibiting B7-H4. Also provided are nucleic acid molecules encoding the antibodies, antigen-binding fragments thereof, and fusion proteins thereof disclosed herein and therapeutic compositions thereof. Disclosed are further methods of using the disclosed antibodies, antigen-binding fragments thereof, and fusion proteins thereof for the treatment of disease.
    Type: Application
    Filed: November 29, 2022
    Publication date: October 5, 2023
    Applicant: Kadmon Corporation, LLC
    Inventors: Dan Lu, Jeegar P. Patel, Tzu-Pei Chang, Zhanna Polonskaya, Faical Miyara
  • Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase
    Publication number: 20230174519
    Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: February 1, 2023
    Publication date: June 8, 2023
    Applicant: Kadmon Corporation, LLC
    Inventors: Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo
  • Human anti-VEGFR-2/KDR antibodies
    Patent number: 11633475
    Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 25, 2023
    Assignee: Kadmon Corporation, LLC
    Inventors: Dan Lu, Zhenping Zhu